Payment overview · 2025
General Payments
$234.37
13 reported records · 9 companies
Healthcare provider profile · identity verified
Laura Purdom, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DANDRIDGE, TN · NPI 1821282997
Verified facts
What the public records show
CMS Open Payments records show Laura Purdom, M.D. received $234.37 in general payments during 2025 across 13 reported records.
Salix Pharmaceuticals, a division of Bausch Health US, LLC accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $55.33 | 23.6% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $36.59 | 15.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.80 | 13.1% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.93 | 10.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.42 | 8.7% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.71 | 8.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.38 | 7.4% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.26 | 7.4% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $13.95 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.37 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $55.33 | 4 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $36.59 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $30.80 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.93 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 40 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 400 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 395 | 105 |
| Lisinopril | Lisinopril | 366 | 101 |
| Omeprazole | Omeprazole | 357 | 96 |
| Gabapentin | Gabapentin | 336 | 48 |
| Alprazolam | Alprazolam | 326 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 294 | 39 |
| Losartan Potassium | Losartan Potassium | 264 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 222 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 175 | 45 |
| Metformin Hcl | Metformin Hcl | 169 | 44 |
| Montelukast Sodium | Montelukast Sodium | 169 | 53 |
| Furosemide | Furosemide | 166 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 39 |
| Tramadol Hcl | Tramadol Hcl | 150 | 26 |
| Sertraline Hcl | Sertraline Hcl | 149 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 50 |
| Simvastatin | Simvastatin | 143 | 34 |
| Meloxicam | Meloxicam | 129 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 37 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 112 | 28 |
| Trazodone Hcl | Trazodone Hcl | 107 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 25 |
| Metformin Hcl Er | Metformin Hcl | 100 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 90 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 89 | 29 |
| Alendronate Sodium | Alendronate Sodium | 88 | 30 |
| Carvedilol | Carvedilol | 87 | 23 |
| Lovastatin | Lovastatin | 86 | 20 |
| Allopurinol | Allopurinol | 83 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 81 | suppressed |
| Potassium Chloride | Potassium Chloride | 81 | 23 |
| Fluoxetine Hcl | Fluoxetine Hcl | 75 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 24 |
| Glipizide | Glipizide | 69 | 20 |
| Glipizide Er | Glipizide | 69 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 21 |
| Ozempic | Semaglutide | 66 | 14 |
| Clonazepam | Clonazepam | 65 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 58 | 50 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Donepezil Hcl | Donepezil Hcl | 56 | 15 |
| Lorazepam | Lorazepam | 55 | suppressed |
| Famotidine | Famotidine | 53 | 23 |
| Terazosin Hcl | Terazosin Hcl | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 18 |
| Fluconazole | Fluconazole | 46 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 46 | 14 |
| Atenolol | Atenolol | 45 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 13 |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Ezetimibe | Ezetimibe | 42 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 11 |
| Eliquis | Apixaban | 40 | 13 |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Prednisone | Prednisone | 39 | 33 |
| Azithromycin | Azithromycin | 37 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 37 | 11 |
| Fenofibrate | Fenofibrate | 37 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 37 | suppressed |
| Glimepiride | Glimepiride | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Jardiance | Empagliflozin | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 18 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Estradiol | Estradiol | 25 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 12 |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Epinephrine | Epinephrine | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.37 · 13 records | Salix Pharmaceuticals, a division of Bausch Health US, LLC | AIRSUPRA, Dexcom G6 Transmitter, ELIQUIS, INGREZZA, Kerendia, LEQVIO, NURTEC ODT, WaveWriter Alpha Prime 16, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error